Rozbeh Jafari
Principal Researcher | Docent
E-mail: rozbeh.jafari@ki.se
Visiting address: SciLifeLab, Tomtebodavägen 23A, 17121 Solna
Postal address: K7 Onkologi-Patologi, K7 Forskning Lehtiö, 171 77 Stockholm
About me
- Dr. Jafari obtained his PhD in biomedical sciences at the department of chemistry and biomedical sciences, Karlstad University, where he developed antibody fragments for cancer immunotherapy of solid tumors. As a postdoc with Prof. Pär Nordlund at the department of biochemistry and biophysics, Karolinska Institutet, he developed the Cellular Thermal Shift Assay (CETSA) and its proteome wide adaptation, Thermal Proteome Profiling (TPP) and studied target and off-target identification and interaction of oncology drugs. He was awarded a assistant professor position from Swedish Childhood Fund in 2016 and the starting grant from Swedish Research Council in 2017 to establish his own research group at the department of oncology-pathology at Karolinska Institutet to apply multi-omic analysis of leukemias. In Feb 2024 he was accepted as Associate Professor in cell and molecular biology at the department of onkologi-patologi.
Research
- We are using and combining state of the art omics methods to obtain detailed pictures of the molecular phenotype of childhood and adult acute lymphoblastic leukemia to identify precision medicine candidates for improved therapy. One fundamental question we currently are trying to address is how cancer genome aberrations influence the functional proteome by combining genomics with proteomics data. This field is known as cancer proteogenomics. In addition to quantitative proteomics we are adding an additional layer of information by capturing the biophysical state of the proteome regardless of its abundance using thermal proteomics which also allows us to identify functional proteoforms with associations to drug sensitivity. We are also investigating the target landscape of current and emerging targeted therapeutics using orthogonal chemical proteomics approaches in order to understand their mechanism of action as well as their potential toxicities.
Selected publications
- Article: NATURE CHEMICAL BIOLOGY. 2023;19(8):962-971
- Article: LEUKEMIA. 2023;37(1):61-71
- Article: NATURE COMMUNICATIONS. 2022;13(1):1691
- Article: FASEB JOURNAL. 2021;35(7):e21741
- Article: NATURE PROTOCOLS. 2014;9(9):2100-2122
- Article: SCIENCE. 2013;341(6141):84-87
Articles
- Article: CELL DEATH & DISEASE. 2024;15(9):694
- Journal article: BLOOD CANCER DISCOVERY. 2024;5(2_Supplement):p30
- Article: NPJ PRECISION ONCOLOGY. 2024;8(1):38
- Article: SCIENTIFIC REPORTS. 2024;14(1):4000
- Journal article: CANCER RESEARCH. 2023;83(7):6612
- Article: NPJ PRECISION ONCOLOGY. 2023;7(1):32
- Article: BIOINFORMATICS ADVANCES. 2023;3(1):vbad143
- Article: NATURE COMMUNICATIONS. 2022;13(1):6226
- Article: CELL DEATH & DISEASE. 2021;12(10):914
- Article: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(5):580-588
- Article: VIRUSES-BASEL. 2020;12(12):E1423-1423
- Journal article: BLOOD. 2020;136:10-11
- Article: NATURE COMMUNICATIONS. 2019;10(1):1519
- Article: ANNALS OF ONCOLOGY. 2016;27(12):2275-2283
- Article: NATURE COMMUNICATIONS. 2016;7:11040
- Article: SCIENCE. 2014;346(6205):1255784
- Article: MICROBIAL CELL FACTORIES. 2011;10:34
- Article: JOURNAL OF IMMUNOLOGICAL METHODS. 2011;364(1-2):65-76
- Article: MABS. 2010;2(6):662-669
- Article: CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 2010;25(4):455-463
- Article: MOLECULAR IMMUNOLOGY. 2007;44(6):1075-1084
- Show more
All other publications
- Preprint: BIORXIV. 2023
- Preprint: RESEARCH SQUARE. 2023
- Conference publication: BLOOD. 2022;140:6299
- Preprint: BIORXIV. 2022
- Preprint: BIORXIV. 2022
- Preprint: RESEARCH SQUARE. 2021
- Preprint: BIORXIV. 2021
- Preprint: SSRN ELECTRONIC JOURNAL. 2020
- Meeting abstract: CANCER RESEARCH. 2016;76:4386
Grants
- Integrative multi-omics for mechanistic insights into acute lymphoblastic leukemia for precision therapiesSwedish Cancer Society: Senior Investigator Award1 July 2024 - 30 June 2027
- Integrative multi-omics for mechanistic insights into acute lymphoblastic leukemia for precision therapiesThe Swedish Cancer Society1 January 2024 - 31 December 2026
- Swedish Cancer Society1 January 2024
- Swedish Research Council1 January 2018 - 31 December 2021
- Predictive therapeutic and resistance biomarkers in childhood leukemia using chemical proteomicsThe Swedish Childhood Cancer Fund1 January 2017 - 31 December 2019
- Predictive therapeutic and resistance biomarkers in childhood leukemia using chemical proteomicsThe Swedish Childhood Cancer Fund1 September 2016 - 31 August 2021
Employments
- Principal Researcher, Department of Oncology-Pathology, Karolinska Institutet, 2024-
Degrees and Education
- Docent, Department of Oncology-Pathology, Karolinska Institutet, 2024
- PhD, Department of Chemistry and Biomedical Sciences, Karlstad University, 2010